Alkem Laboratories Limited has announced a significant partnership with US-based Sonnet BioTherapeutics Holdings, Inc. to develop, manufacture, and commercialize the drug candidate “SON-080” for the treatment of diabetic peripheral neuropathy (DPN) in India.
SON-080 has shown promising results in phase 1b clinical trials, demonstrating potential for nerve regeneration and a reduction in neuropathy symptoms. Under the agreement, Alkem will lead clinical development in India, with support from Sonnet, and will work towards both global and Indian regulatory filings.
Diabetic peripheral neuropathy is a widespread complication affecting a substantial portion of people with diabetes in India, often leading to serious health issues such as foot injuries and amputations. This partnership is a step towards addressing the growing healthcare burden associated with diabetes-related complications in the country.
Dr. Akhilesh Sharma, President and Chief Medical Officer of Alkem, expressed optimism about the collaboration, highlighting the potential of SON-080 to bring a new treatment option to a large patient population in India.
Pankaj Mohan, CEO of Sonnet, also shared excitement about the partnership, looking forward to advancing SON-080 into phase 2 clinical development with Alkem’s expertise.
This agreement reinforces Alkem’s commitment to addressing chronic diseases in India and reflects the company’s strategic focus on developing therapies for high-prevalence conditions.
